Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2019)
Arbutus Biopharma (ABUS) posted Cash from Restructuring of -$66000.0 for Q4 2019, up 52.17% sequentially from -$138000.0 in Q3 2019, and down 111.76% YoY from $561000.0 in Q4 2018.
Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2019) Analysis & Trends
Arbutus Biopharma has reported Cash from Restructuring for 2 years, with the latest figure at -$66000.0 in Q4 2019.
- Quarterly Cash from Restructuring fell 111.76% year-over-year to -$66000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was -$983000.0 (down 159.04% YoY) and the FY2019 annual result came in at -$983000.0, down 173.85% from the prior year.
- Cash from Restructuring improved to -$66000.0 in Q4 2019 per ABUS's latest filing, from -$138000.0 in the prior quarter.
- Over five years, Cash from Restructuring peaked at $1.0 million in Q1 2018 and troughed at -$640000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -66,000.00 |
| Sep 30, 2019 | -138,000.00 |
| Jun 30, 2019 | -640,000.00 |
| Mar 31, 2019 | -139,000.00 |
| Dec 31, 2018 | 561,000.00 |
| Sep 30, 2018 | -320,000.00 |
| Jun 30, 2018 | 395,000.00 |
| Mar 31, 2018 | 1.03 Mn |